fostamatinib ITP
Selected indexed studies
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. (Am J Hematol, 2018) [PMID:29696684]
- Fostamatinib (Tavalisse) for ITP. (Med Lett Drugs Ther, 2019) [PMID:30845102]
- How we treat primary immune thrombocytopenia in adults. (J Hematol Oncol, 2023) [PMID:36658588]
_Worker-drafted node — pending editorial review._
Connections
fostamatinib ITP is a side effect of
Sources
- Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. (2024) pubmed
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. (2018) pubmed
- Fostamatinib (Tavalisse) for ITP. (2019) pubmed
- How we treat primary immune thrombocytopenia in adults. (2023) pubmed
- Novel therapeutics and future directions for refractory immune thrombocytopenia. (2023) pubmed
- Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy. (2024) pubmed
- Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study. (2025) pubmed
- Immune thrombocytopenia. (2021) pubmed
- Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. (2020) pubmed
- The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP? (2024) pubmed